Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open, Single-arm, Single-dose, Dose-escalation, and Expanded Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of LY-M001 Injection in Adult Patients With Type I Gaucher Disease

NCT06818838 is registered in ClinicalTrials.gov with Lingyi Biotech Co., Ltd. as lead sponsor.

NCT NCT06818838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06818838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open, Single-arm, Single-dose, Dose-escalation, and Expanded Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of LY-M001 Injection in Adult Patients With Type I Gaucher Disease
Lead sponsor
Lingyi Biotech Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 5, 2024
Completion date
July 30, 2031
Enrollment
12 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gaucher disease type 1